U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H13NO5
Molecular Weight 179.1714
Optical Activity ( + )
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLUCOSAMINE

SMILES

N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO

InChI

InChIKey=FZHXIRIBWMQPQF-SLPGGIOYSA-N
InChI=1S/C6H13NO5/c7-3(1-8)5(11)6(12)4(10)2-9/h1,3-6,9-12H,2,7H2/t3-,4+,5+,6+/m0/s1

HIDE SMILES / InChI

Molecular Formula C6H13NO5
Molecular Weight 179.1714
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Glucosamine is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids. Glucosamine is part of the structure of the polysaccharides chitosan and chitin, which compose the exoskeletons of crustaceans and other arthropods, as well as the cell walls of fungi and many higher organisms. Glucosamine is one of the most abundant monosaccharides. It is produced commercially by the hydrolysis of crustacean exoskeletons or, less commonly, by fermentation of a grain such as corn or wheat. Oral glucosamine is a dietary supplement and is not a pharmaceutical drug. It is illegal in the US to market any dietary supplement as a treatment for any disease or condition. Glucosamine is marketed to support the structure and function of joints, and the marketing is targeted to people suffering from osteoarthritis. Commonly sold forms of glucosamine are glucosamine sulfate, glucosamine hydrochloride, and N-acetylglucosamine. Of the three commonly available forms of glucosamine, only glucosamine sulfate is given a "likely effective" rating for treating osteoarthritis. Glucosamine is often sold in combination with other supplements such as chondroitin sulfate and methylsulfonylmethane. Glucosamine, along with commonly used chondroitin, is not routinely prescribed to treat people who have symptomatic osteoarthritis of the knee, as there is insufficient evidence that this treatment is helpful. One clinical study over three years showed that glucosamine in doses of 1500 mg per day is safe to use. Glucosamine with or without chondroitin elevates the international normalized ratio (INR) in individuals who are taking the blood thinner, warfarin. It may also interfere with the efficacy of chemotherapy for treating cancer symptoms. Adverse effects may include stomach upset, constipation, diarrhea, headache, and rash. There are case reports of people who have chronic liver disease and a worsening of their condition with glucosamine supplementation. Glucosamine is naturally present in the shells of shellfish, animal bones, bone marrow, and fungi. D-Glucosamine is made naturally in the form of glucosamine-6-phosphate, and is the biochemical precursor of all nitrogen-containing sugars. Specifically in humans, glucosamine-6-phosphate is synthesized from fructose 6-phosphate and glutamine by glutamine—fructose-6-phosphate transaminase as the first step of the hexosamine biosynthesis pathway. The end-product of this pathway is uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), which is then used for making glycosaminoglycans, proteoglycans, and glycolipids. As the formation of glucosamine-6-phosphate is the first step for the synthesis of these products, glucosamine may be important in regulating their production; however, the way that the hexosamine biosynthesis pathway is actually regulated, and whether this could be involved in contributing to human disease remains unclear.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Glucosamine

Approved Use

Unknown
Primary
Glucosamine

Approved Use

Unknown
Primary
Oral Lichen Planus

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2224 ng/mL
1500 mg 1 times / day steady-state, oral
dose: 1500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GLUCOSAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2125 ng/mL
1500 mg 1 times / day steady-state, oral
dose: 1500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GLUCOSAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1069.2 ng/mL
750 mg 1 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GLUCOSAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1601.9 ng/mL
1500 mg 1 times / day steady-state, oral
dose: 1500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GLUCOSAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2503.1 ng/mL
3000 mg 1 times / day steady-state, oral
dose: 3000 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GLUCOSAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
16874 ng × h/mL
1500 mg 1 times / day steady-state, oral
dose: 1500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GLUCOSAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
16718 ng × h/mL
1500 mg 1 times / day steady-state, oral
dose: 1500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GLUCOSAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
9697 ng × h/mL
750 mg 1 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GLUCOSAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
14564 ng × h/mL
1500 mg 1 times / day steady-state, oral
dose: 1500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GLUCOSAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
22095 ng × h/mL
3000 mg 1 times / day steady-state, oral
dose: 3000 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GLUCOSAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.6 h
1500 mg 1 times / day steady-state, oral
dose: 1500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GLUCOSAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5.8 h
1500 mg 1 times / day steady-state, oral
dose: 1500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GLUCOSAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
unknown
GLUCOSAMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
100%
GLUCOSAMINE plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
3000 mg 1 times / day steady-state, oral
Highest studied dose
Dose: 3000 mg, 1 times / day
Route: oral
Route: steady-state
Dose: 3000 mg, 1 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride.
2008-09
Disease-modifying effects of glucosamine HCl involving regulation of metalloproteinases and chemokines activated by interleukin-1beta in human primary synovial fibroblasts.
2008-05-01
Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down-regulation of mitogen-activated protein kinase-mediated nuclear factor-kappaB signaling.
2008-03
A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial.
2008-02-17
Sulfated glucosamine inhibits oxidation of biomolecules in cells via a mechanism involving intracellular free radical scavenging.
2008-01-28
Glucosamine and its N-acetyl-phenylalanine derivative prevent TNF-alpha-induced transcriptional activation in human chondrocytes.
2008-01-05
Influence of glucosamine sulphate on oxidative stress in human osteoarthritic chondrocytes: effects on HO-1, p22(Phox) and iNOS expression.
2008-01
[Determination of glucosamine hydrochloride in complex formula by RP-HPLC coupled with evaporative light scattering detection].
2007-11
The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes.
2007-11
Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study.
2007-11
Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351].
2007-10-31
Evaluation of the suppressive actions of glucosamine on the interleukin-1beta-mediated activation of synoviocytes.
2007-10
Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner.
2007-09-21
Treatment of primary and secondary osteoarthritis of the knee.
2007-09
[A comparison study on the physical/chemical properties and immunomodulatory activities of mycelial polysaccharide extracts from five Ganoderma species].
2007-08
Modulation of articular chondrocyte proliferation and anionic glycoconjugate synthesis by glucosamine (GlcN), N-acetyl GlcN (GlcNAc) GlcN sulfate salt (GlcN.S) and covalent glucosamine sulfates (GlcN-SO4).
2007-08
[Effect of glucosamine sulfate on the analgesic and ulcerogenic activity of ketoprofen].
2007-07-27
[Efficacy and safety evaluation of glucosamine hydrochloride in the treatment of osteoarthritis].
2007-07-15
Sulfated glucosamine inhibits MMP-2 and MMP-9 expressions in human fibrosarcoma cells.
2007-07-15
Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions.
2007-07
Glucosamine for pain in osteoarthritis: why do trial results differ?
2007-07
Collagen Synthesis in tenocytes, ligament cells and chondrocytes exposed to a combination of Glucosamine HCl and chondroitin sulfate.
2007-06
Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation.
2007-06
The effects of glucosamine hydrochloride on subchondral bone changes in an animal model of osteoarthritis.
2007-05
Glucosamine inhibits LPS-induced COX-2 and iNOS expression in mouse macrophage cells (RAW 264.7) by inhibition of p38-MAP kinase and transcription factor NF-kappaB.
2007-05
Establishment of a novel corneal endothelial cell line from domestic rabbit, Oryctolagus curiculus.
2007-04
Preparation of glucosamine from exoskeleton of shrimp and predicting production yield by response surface methodology.
2007-03-21
Factors affecting trypanosome maturation in tsetse flies.
2007-02-21
Systematic review of clinical trials of treatments for osteoarthritis in dogs.
2007-02-15
[The influence of experimental therapy on the dynamics of endogenous glucosamine content in laboratory animals with nephropathy].
2007-01-11
Effects of glucosamine administration on patients with rheumatoid arthritis.
2007-01
Glucosamine hydrochloride for the treatment of osteoarthritis symptoms.
2007
Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study.
2007
Glucosamine affects intracellular signalling through inhibition of mitogen-activated protein kinase phosphorylation in human chondrocytes.
2007
Glucosamine prevents in vitro collagen degradation in chondrocytes by inhibiting advanced lipoxidation reactions and protein oxidation.
2007
Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis.
2007
An analysis of high glucose and glucosamine-induced gene expression and oxidative stress in renal mesangial cells.
2006-12-21
Glucosamine sulfate inhibits proinflammatory cytokine-induced icam-1 production in human conjunctival cells in vitro.
2006-12
Enhanced chondrogenic differentiation of murine embryonic stem cells in hydrogels with glucosamine.
2006-12
Glucosamine sulfate inhibits leukocyte adhesion in response to cytokine stimulation of retinal pigment epithelial cells in vitro.
2006-11
Evidence-based practice: review of clinical evidence on the efficacy of glucosamine and chondroitin in the treatment of osteoarthritis.
2006-10
Glucosamine sulfate-induced apoptosis in chronic myelogenous leukemia K562 cells is associated with translocation of cathepsin D and downregulation of Bcl-xL.
2006-10
Double blind investigation of the effects of oral supplementation of combined glucosamine hydrochloride (GHCL) and chondroitin sulphate (CS) on stride characteristics of veteran horses.
2006-08
Arthritic disease suppression and cartilage protection with glycosaminoglycan polypeptide complexes (Peptacans) derived from the cartilage extracellular matrix: a novel approach to therapy.
2006-08
An optimized reverse-phase high performance liquid chromatographic method for evaluating percutaneous absorption of glucosamine hydrochloride.
2006-05-03
Determination of the degree of acetylation of chitosan by UV spectrophotometry using dual standards.
2006-05-01
Glucosamine sulfate inhibits TNF-alpha and IFN-gamma-induced production of ICAM-1 in human retinal pigment epithelial cells in vitro.
2006-02
Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta.
2006
Inhibitory effects of glucosamine on lipopolysaccharide-induced activation in microglial cells.
2005-12
[Experience with glucosamine hydrochloride in the treatment of patients with osteoarthrosis].
2005
Patents

Sample Use Guides

In Vivo Use Guide
In clinical studies of arthritis, glucosamine dosage has typically been 1.5 g/day, as a single dose or in divided doses.
Route of Administration: Oral
To induce insulin resistance 3T3-L1 adipocytes were treated with DMEM containing 10% FBS and 2 mM glucosamine, and in the absence of glucose, glutamine, and insulin. Since glucosamine bypasses the GFAT step to enter the hexosamine pathway, glutamine is not needed for glucosamineinduced insulin resistance
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:33:13 GMT 2025
Edited
by admin
on Mon Mar 31 17:33:13 GMT 2025
Record UNII
N08U5BOQ1K
Record Status FAILED
Record Version
  • Download
Name Type Language
MEDIFLEX
Preferred Name English
GLUCOSAMINE
HSDB   INCI   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN   INCI  
Official Name English
CHITOSAMINE
Common Name English
GLUCOSAMINE [VANDF]
Common Name English
GLUCOPYRANOSE, 2-AMINO-2-DEOXY-, D-
Systematic Name English
D-(+)-GLUCOSAMINE
Systematic Name English
(3R,4R,5S,6R)-3-AMINO-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-2,4,5-TRIOL
Systematic Name English
GLUCOPYRANOSE, 2-AMINO-2-DEOXY-
Systematic Name English
(2R,3R,4S,5R)-2-AMINO-3,4,5,6-TETRAHYDROXYHEXANAL
Systematic Name English
GLUCOSAMINE [MI]
Common Name English
GLUCOSAMINE [USAN]
Common Name English
Glucosamine [WHO-DD]
Common Name English
D-GLUCOPYRANOSE, 2-AMINO-2-DEOXY-
Systematic Name English
GLUCOSAMINE [MART.]
Common Name English
2-AMINO-2-DEOXY-D-GLUCOSE
Systematic Name English
GLUCOSAMINE [HSDB]
Common Name English
D-GLUCOSE, 2-AMINO-2-DEOXY-
Systematic Name English
glucosamine [INN]
Common Name English
Classification Tree Code System Code
LOINC 80093-8
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
WHO-VATC QM01AX05
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
LIVERTOX NBK547949
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
WHO-ATC M01AX05
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
LOINC 80098-7
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
DSLD 2165 (Number of products:92)
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
Code System Code Type Description
WIKIPEDIA
GLUCOSAMINE
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
EPA CompTox
DTXSID4023098
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
EVMPD
SUB07937MIG
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
CONCEPT Dietary Supplement
ChEMBL
CHEMBL606759
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
CHEBI
17315
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
LACTMED
Glucosamine
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
SMS_ID
100000092644
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
CHEBI
20993
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
CHEBI
47977
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
DRUG CENTRAL
1307
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
CAS
3416-24-8
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
FDA UNII
N08U5BOQ1K
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
MESH
D005944
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
CAS
90-77-7
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
ALTERNATIVE
CAS
34948-66-8
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
ALTERNATIVE
NCI_THESAURUS
C83731
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
INN
3120
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
MERCK INDEX
m5764
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY Merck Index
CHEBI
5417
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
PUBCHEM
3034366
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
HSDB
7469
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
DAILYMED
N08U5BOQ1K
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
DRUG BANK
DB01296
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
RXCUI
4845
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY RxNorm
ECHA (EC/EINECS)
222-311-2
Created by admin on Mon Mar 31 17:33:13 GMT 2025 , Edited by admin on Mon Mar 31 17:33:13 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY